Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS) - European Medical Journal
×

Browse

Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS)

|
Oncology

At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen Lachmann, MA, MB BChir, MD, FRCP, from the Royal Free London NHS Foundation Trust, London, UK discusses the results of a trial which analysed the use of canakinumab to treat tumour necrosis factor receptor-associated periodic syndrome (TRAPS), and how they relate to her own experiences in the UK.